西格列汀联合二甲双胍治疗初发2型糖尿病的临床观察被引量：7

下载PDF

导出

摘要目的本文主要探讨2型糖尿病患者给予西格列汀联合二甲双胍治疗的临床效果。方法我院2015年7月至2016年9月收治的初发2型糖尿病患者中选取120例患者随机分成对照组和观察组,分别给予二甲双胍和西格列汀联合二甲双胍进行治疗,观察比较两组的治疗前及治疗12周后患者的空腹血糖(FPG)及餐后2h血糖(2hPG)和糖化血红蛋白(HbA1c)。结果治疗后两组患者与治疗前比较,差异均有统计学意义(P <0. 05);且治疗后观察组的FPG,2hPG,HbA1c水平明显优于对照组,差异均有统计学意义(P <0. 05);两组不良反应比较,差异无统计学意义(P> 0. 05)。结论西格列汀联合二甲双胍治疗初发2型糖尿病疗效显著,可以有效降低患者血糖,其安全性高,值得大力推广。

作者高建林

机构地区天津市宝坻区中医医院

出处《海峡药学》 2018年第10期114-115,共2页 Strait Pharmaceutical Journal

关键词西格列汀二甲双胍 2型糖尿病

分类号 R969.4 [医药卫生—药理学]

引文网络
相关文献

参考文献5

1中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中国糖尿病杂志,2014,22(8). 被引量：6712
2张婷.从2型糖尿病的发病机制中分析糖尿病治疗的新策略[J].世界临床医学,2017,11(10):128-129. 被引量：1
3焦阳,李小英.二甲双胍降糖作用机制研究进展[J].中华糖尿病杂志,2016,8(11):696-698. 被引量：11
4金阳,刘治军.二肽肽酶-4抑制剂西格列汀相关的药物相互作用[J].中国医院药学杂志,2013,33(13):1085-1088. 被引量：6
5王娟.西格列汀治疗2型糖尿病的临床研究进展讨论[J].现代诊断与治疗,2016,27(15):2906-2907. 被引量：3

二级参考文献42

1Golightly LK,Drayna CC, McDermott MT. Comparative Clini-cal Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors [J].Clin Pharmacokinet 2012,51 .8) :501-514.
2Chu XY,Bleasby K,Yabut J.et al. Transport of the dipeptidylpeptidase-4 inhibitor sitagliptin by human organic anion trans-porter 3,organic anion transporting polypeptide 4C1 ,and multi-drug resistance P-glycoprotein [ J ]. J Pharmacol Exp Ther.2007,321(2):673-683.
3Mistry GC.Bergman AJ.Zheng W.etal. Sitagliptin,an dipepti-dyl peptidase-4 inhibitor,does not alter the pharmacokinetics ofthe sulphonylurea.glyburide,in healthy subjects[J]. Br J ClinPharmacol,2008*66(1) :36-42.
4Mistry GC,Bergman AJ,Luo Wet aL Multiple-dose adminis-tration of sitagliptin,a dipeptidyl peptidase-4 inhibitor,does notalter the single-dose pharmacokinetics of rosiglitazone inhealthy subjects[J]. J Clin Pharmacol, 2007,47(2) : 159-164.
5Herman GA,Bergman A, Yi B,et al. Tolerability and pharma-cokinetics of metformin and the dipeptidyl peptidase-4 inhibitorsitagliptin when co-administered in patients with type 2 diabe-tes[J]. Curr Med Res Opin,2006,22(10) : 1939-1947.
6Kasichayanula S,Liu X, Shyu WC, et al. Lack of pharmacoki-netic interaction between dapagliflozin, a novel sodium-glucosetransporter 2 inhibitor,and metformin.pioglitazone, glimepirideor sitagliptin in healthy subjects [J]. Diabetes Obes Metab,2011,13(1):47-54.
7Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacoki-netic interaction between ipragliflozin and sitagliptin, pioglita-zone, or glimepiride in healthy subject's [J ]. Diabetes ObesMetab ,2012,14(10); 937-943.
8DiGregorio RV,Pasikhova Y. Rhabdomyolysis caused by a po-tential sitagliptin-lovastatin interaction [J]. Pharmacotherapy,2009,29(3):352-356.
9Khao DP,Kohrt HE,Kugler J. Renal failure and rhabdomyoly-sis associated with sitagliptin and simvastatin use [J ]. DiabetMed,2(K)8,25 :1229 1230.
10Boucher BJ. Renal failure and rhabdomyolysis associated withsitagliptin and simvastatin use. But what about the amiodarone[J]. Diabet Med,2009,26(2) ; 192-193.